Time filter

Source Type

Ago Are, Nigeria

Olabisi Onabanjo University, Ago-Iwoye is a state-owned and -operated university in Ago-Iwoye, Ogun State Nigeria. The university was founded July 7, 1982 as Ogun State University and was renamed Olabisi Onabanjo University on May 29, 2001 in honour of Chief Olabisi Onabanjo, whose efforts as the then civilian governor of Ogun State gave birth to the university.The university has had a total output of 10,291 graduates and 1,697 postgraduates.Olabisi Onabanjo University has multiple campuses. The Main Campus in Ago-Iwoye is popularly called Permanent Site by the students and a Mini Campus which is home to the Science Department. Faculty of Agriculture is in Aiyetoro, faculty of Engineering is in Ibogun, college of Medicine is in Shagamu, department of Mass Communication in Ijebu-Igbo, faculty of Pharmacy and department Biochemistry is at Ikenne.Students and alumni of the Olabisi Onabanjo University are addressed as ‘Great OSUITES.’ This term usually gives a feeling of belonging to the addresser and addressee.Information and activities amidst Students are communicated through the school's portal as well as notable privately owned magazines such as ' Inside OOU magazine', ' OOU Vanguard' and a few others. Wikipedia.

Oladapo O.T.,Olabisi Onabanjo University
Cochrane database of systematic reviews (Online) | Year: 2012

Advance community distribution of misoprostol for preventing or treating postpartum haemorrhage (PPH) has become an attractive strategy to expand uterotonic coverage to places where conventional uterotonic use is not feasible. However, the value and safety of this strategy remain contentious. To assess the effectiveness and safety of a strategy of advance misoprostol distribution for PPH prevention and treatment in non-facility births. We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (5 October 2011). We did not apply any language restrictions. Randomised or quasi-randomised controlled trials of advance misoprostol distribution to lay health workers or pregnant women compared with usual care for PPH prevention or treatment in non-facility births. We excluded studies without any form of random design. Two review authors independently assessed trial eligibility for inclusion. The search strategies identified three studies. None of the studies met the inclusion criteria. There is no evidence from randomised or quasi-randomised trials on the benefits or risks of a strategy of advance misoprostol distribution for PPH prevention or treatment in non-facility births. In view of the increasing interest to scale up this strategy, there is an urgent need for large and well-designed randomised trials to evaluate its comparative benefits and risks.

Ebesunun M.O.,Olabisi Onabanjo University
The Pan African medical journal | Year: 2012

Elevated plasma total homocysteine (tHcy) concentration has been associated with an increased risk for cardiovascular events in type 2 diabetic individuals independent of conventional risk factors. Available study in Nigerian-Africans is scare. Seventy (30 males) and (40 females) type 2 diabetes mellitus, with age mean of 54 ± 11.52 years were selected for this study and thirty apparently healthy volunteers were included as controls. The biochemical parameters and anthropometric indices were determined using standard procedures. Significant increases were obtained in body weight, body mass index (p<0.001) and waist circumference (p<0.012) when compared with the corresponding control values respectively. The fasting plasma glucose (p<0.01), tHcy (p<0.02), and triglyceride (p<0.03) were significantly higher in the diabetes group when compared with the corresponding control values. The plasma folic acid and vitamin B(12) (p<0.05) were significantly reduced compared to the control values. The tHcy (p<0.01) was significantly higher in the males when compared with the corresponding female value. Significant decrease was obtained in the plasma triglyceride (p<0.003) in the male patients when compared with the female patients. Our result showed increased plasma tHcy, triglyceride and waist circumference as well as decreased folic acid and vitamin B(12) in type 2 diabetes mellitus. These alterations are risk factors for premature CVD events.

Oladapo O.T.,Olabisi Onabanjo University
International Journal of Gynecology and Obstetrics | Year: 2012

The lack of clear interpretation of clinical and operational evidence on misoprostol use for postpartum hemorrhage (PPH) in the community may jeopardize the realization of its full potential for improving women's survival. This paper highlights the usefulness of misoprostol in addressing PPH in the community within the limits of available research evidence. There is now substantial evidence to support the beneficial effects of 600 μg of oral misoprostol for PPH prevention in the community, with a trend toward better protection against severe PPH morbidity, and particularly when administered by less skilled or lay caregivers. Although there is tangible evidence to show that 800 μg of sublingual misoprostol has important benefits for PPH treatment where there is no access to oxytocin, there is presently no direct evidence to indicate that less skilled or lay caregivers can safely use it to treat PPH in the community. Operational research evidence indicates that advance community distribution of misoprostol to pregnant women for postpartum self-use is a feasible strategy to ensure availability of the drug at the time of birth. The evidence is, however, limited by its quality to establish whether the benefits of such a strategy truly outweigh the potential harms. It is time for the international community to focus on improving PPH-related outcomes by scaling up what is currently guided by hard evidence and join forces to address unanswered questions through high-quality research. © 2012 International Federation of Gynecology and Obstetrics.

Ajibesin K.K.,Olabisi Onabanjo University
Research Journal of Medicinal Plant | Year: 2011

Dacryodes edulis is a dioecious, shade loving, evergreen tree, indigenous to the Gulf of Guinea and widely cultivated in other tropical parts of Africa for its fruit. The edible fruit to which the plant owes its principal values is a rich source of nutrients such as lipids, vitamins and protein. The fruit yields a high content of fixed and essential oils. The fruits are highly consumed and traded locally and internationally, conferring enormous economic value on the plant. The plant has long been used in the traditional medicine of some African countries to treat various ailments such as wound, skin diseases, dysentery and fever. The extracts and secondary metabolites have been found to show biological activities such as antimicrobial, antioxidant and anti sickle cell anemia. A wide range of chemical constituents such as terpenes, flavonoids, tannins, alkaloids and saponins have been isolated from the plant. This review provides a comprehensive detail of the plant's ethnomedicinal uses, biological effects, chemical constituents and economic property as a medicinal plant.©2011 Academic Journals Inc.

Oladapo O.T.,Olabisi Onabanjo University
Cochrane database of systematic reviews (Online) | Year: 2012

Various pharmacologic and non-pharmacologic interventions have been used to suppress lactation after childbirth and relieve associated symptoms. Despite the large volume of literature on the subject, there is currently no universal guideline on the most appropriate approach for suppressing lactation in postpartum women. To evaluate the effectiveness and safety of interventions used for suppression of lactation in postpartum women (who have not breastfed or expressed breastmilk) to determine which approach has the greatest comparative benefits with least risk. We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (30 June 2012). Randomised trials evaluating the effectiveness of treatments used for suppression of postpartum lactation. Two review authors independently assessed trial quality and extracted data. We included 62 trials (6428 women). Twenty-two trials did not contribute data to the meta-analyses. The trials were generally small and of limited quality. Three trials (107 women) indicated that bromocriptine significantly reduced the proportion of women lactating compared with no treatment at or within seven days postpartum (three trials, 107 women; risk ratio (RR) 0.36, 95% confidence interval (CI) 0.24 to 0.54). Seven trials involving oestrogen preparations (diethylstilbestrol, quinestrol, chlorotrianisene, hexestrol) suggested that they significantly reduced the proportion of lactating women compared with no treatment at or within seven days postpartum (RR 0.40, 95% CI 0.29 to 0.56). We found no trials comparing non-pharmacologic methods with no treatment. Trials comparing bromocriptine with other pharmacologic agents such as methergoline, prostaglandins, pyridoxine, carbegoline, diethylstilbestrol and cyclofenil suggested similarity in their effectiveness. Side effects were poorly reported in the trials and no case of thromboembolism was recorded in the four trials that reported it as an outcome. There is weak evidence that some pharmacologic treatments (most of which are currently unavailable to the public) are better than no treatment for suppressing lactation symptoms in the first postpartum week. No evidence currently exists to indicate whether non-pharmacologic approaches are more effective than no treatment. Presently, there is insufficient evidence to address the side effects of methods employed for suppressing lactation. When women desire treatment, bromocriptine may be considered where it is registered for lactation suppression in those without predisposition to its major side effects of public concerns. Many trials did not contribute data that could be included in analyses. Large randomised trials are needed to compare the effectiveness of pharmacologic (especially bromocriptine) and non-pharmacologic methods with no treatment. Such trials should consider the acceptability of the intervention and lactation symptoms of concern to women and be large enough to detect clinically important differences in major side effects between comparison groups.

Discover hidden collaborations